Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer

Figure 3

Prognostic impact of RRM1, RRM2, and RRM2B in TCGA-LIHC. (a) Kaplan-Meier overall survival analysis between low () and high () expression of RRM1. (b) Kaplan-Meier overall survival analysis between low () and high () expression of RRM2. (c) Kaplan-Meier overall survival analysis between low () and high () expression of RRM2B. (d) Kaplan-Meier disease-specific survival analysis between low () and high () expression of RRM1. (e) Kaplan-Meier disease-specific survival analysis between low () and high () expression of RRM2. (f) Kaplan-Meier disease-specific survival analysis between low () and high () expression of RRM2B. (g) The receiver operating characteristic (ROC) curve for the diagnosis of liver cancer based on RRM1. (h) The ROC curve for the diagnosis of liver cancer based on RRM2. (i) The ROC curve for the diagnosis of liver cancer based on RRM2B.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)